Remdesivir in COVID-19 Patients with Impaired Renal Function.
作者信息
Gevers Sanna, Welink Jan, van Nieuwkoop Cees
机构信息
Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
Department of Internal Medicine, Haga Teaching Hospital, The Hague, The Netherlands.
出版信息
J Am Soc Nephrol. 2021 Feb 1;32(2):518-519. doi: 10.1681/ASN.2020101535. Epub 2021 Jan 21.
Abstract
摘要
相似文献
1
Remdesivir in COVID-19 Patients with Impaired Renal Function.瑞德西韦用于肾功能受损的新冠肺炎患者
J Am Soc Nephrol. 2021 Feb 1;32(2):518-519. doi: 10.1681/ASN.2020101535. Epub 2021 Jan 21.
2
Exploration for the effect of renal function and renal replacement therapy on pharmacokinetics of remdesivir and GS-441524 in patients with COVID-19: A limited case series.探索肾功能和肾脏替代疗法对 COVID-19 患者瑞德西韦和 GS-441524 药代动力学的影响：一项有限的病例系列研究。
Clin Transl Sci. 2022 Mar;15(3):732-740. doi: 10.1111/cts.13194. Epub 2021 Nov 20.
3
Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function.瑞德西韦对 COVID-19 合并肾功能受损住院患者不良肾脏结局的影响。
PLoS One. 2023 Feb 27;18(2):e0279765. doi: 10.1371/journal.pone.0279765. eCollection 2023.
4
A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.有效警示还是临床传闻：多中心匹配队列中肾功能损害患者使用瑞德西韦的安全性结局评估。
Antimicrob Agents Chemother. 2021 Jan 20;65(2). doi: 10.1128/AAC.02290-20.
5
Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database.瑞德西韦治疗 COVID-19 相关的潜在肾损伤：药物警戒数据库分析。
Cad Saude Publica. 2021 Nov 12;37(10):e00077721. doi: 10.1590/0102-311X00077721. eCollection 2021.
6
Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease.瑞德西韦对终末期肾病住院COVID-19患者的疗效。
World J Crit Care Med. 2022 Jan 9;11(1):48-57. doi: 10.5492/wjccm.v11.i1.48.
7
Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.瑞德西韦的药代动力学及其药物相互作用模拟
J Pharm Pharm Sci. 2021;24:277-291. doi: 10.18433/jpps32011.
8
Renal and Hepatic Outcomes after Remdesivir Therapy in Coronavirus Disease-2019-Positive Patients with Renal Dysfunction at Baseline or after Starting Therapy.瑞德西韦治疗新冠肺炎合并基线肾功能异常或治疗后肾功能异常患者的肾脏和肝脏结局。
Saudi J Kidney Dis Transpl. 2021 Jul-Aug;32(4):1034-1042. doi: 10.4103/1319-2442.338277.
9
Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.瑞德西韦与急性肾衰竭：世卫组织安全数据库的比例失调分析显示出的潜在安全性信号。
Clin Pharmacol Ther. 2021 Apr;109(4):1021-1024. doi: 10.1002/cpt.2145. Epub 2021 Jan 16.
10
Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19.OATP4C1 在雷米昔韦和其核苷类似物 GS-441524 的肾脏处置中的作用：首个获批用于 COVID-19 患者的药物。
J Pharm Pharm Sci. 2021;24:227-236. doi: 10.18433/jpps31813.
引用本文的文献
1
Repurposing Niclosamide as a Novel Anti-SARS-CoV-2 Drug by Restricting Entry Protein CD147.通过靶向进入蛋白CD147将氯硝柳胺重新用作新型抗SARS-CoV-2药物
Biomedicines. 2023 Jul 18;11(7):2019. doi: 10.3390/biomedicines11072019.
2
Repurposing niclosamide as a novel anti-SARS-Cov-2 drug by restricting entry protein CD147.通过抑制进入蛋白CD147将氯硝柳胺重新用作新型抗SARS-CoV-2药物。
Res Sq. 2023 Apr 13:rs.3.rs-2763207. doi: 10.21203/rs.3.rs-2763207/v1.
3
Remdesivir-Associated Acute Liver Failure in a COVID-19 Patient: A Case Report and Literature Review.一名新冠肺炎患者出现与瑞德西韦相关的急性肝衰竭：病例报告及文献综述
Cureus. 2023 Jan 26;15(1):e34221. doi: 10.7759/cureus.34221. eCollection 2023 Jan.
4
Authors' Reply.作者回复。
J Am Soc Nephrol. 2021 Feb 1;32(2):519-520. doi: 10.1681/ASN.2020121692. Epub 2021 Jan 21.
5
Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: a self-controlled case series study.瑞德西韦在 COVID-19 住院患者中的使用与急性肾损伤和急性肝损伤的风险：一项自身对照病例系列研究。
Aliment Pharmacol Ther. 2022 Jul;56(1):121-130. doi: 10.1111/apt.16894. Epub 2022 Mar 22.
Zotero 插件